Erasmus MC

erasmusmc.nl

Erasmus MC is the largest and most versatile of the eight university medical centers in the Netherlands. At Erasmus MC you create your own opportunities. A conscious choice for work that matters, both nationally and internationally, at the heart of our multicultural home base of Rotterdam. Working from the heart. Together with people, for people.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

RIDGEBACK BIOTHERAPEUTICS LP ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION APPROVEL OF EBANGATM FOR EBOLA

Ebanga | December 29, 2020

news image

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...

Read More

Industrial Impact

SENDA BIOSCIENCES BOLSTERS EXECUTIVE LEADERSHIP TEAM

Senda Biosciences | October 20, 2022

news image

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the appointments of Lori Rudolph-Owen, Ph.D., as Chief Operating Officer, and Barbara Bispham, J.D., as SVP, General Counsel. "We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization. Each of these seasoned executives brings the skills and experience necessary to h...

Read More

Cell and Gene Therapy

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

news image

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More

Cell and Gene Therapy

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

news image

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More
news image

Medical

RIDGEBACK BIOTHERAPEUTICS LP ANNOUNCES THE U.S. FOOD AND DRUG ADMINISTRATION APPROVEL OF EBANGATM FOR EBOLA

Ebanga | December 29, 2020

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...

Read More
news image

Industrial Impact

SENDA BIOSCIENCES BOLSTERS EXECUTIVE LEADERSHIP TEAM

Senda Biosciences | October 20, 2022

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the appointments of Lori Rudolph-Owen, Ph.D., as Chief Operating Officer, and Barbara Bispham, J.D., as SVP, General Counsel. "We're delighted to add Lori and Barbara to the Senda leadership team as we work to build a world-class organization. Each of these seasoned executives brings the skills and experience necessary to h...

Read More
news image

Cell and Gene Therapy

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More
news image

Cell and Gene Therapy

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us